Details of the Drug

General Information of Drug (ID: DM67PWD)

Drug Name

Etilefrine

Synonyms

etilefrine hydrochloride; 943-17-9; Etilefrine HCl; Circupon; Kertasin; Effontil; 534-87-2; 3-[2-(ethylamino)-1-hydroxyethyl]phenol hydrochloride; Effortilvet; Phetasin; Updormin; Pulsamin; Apocretin; Phetanol; Funasol; Ethyl adrianol; Tonus-Forte; Etilefrin Hydrochloride; Eti-Puren; 3-(2-(Ethylamino)-1-hydroxyethyl)phenol hydrochloride; 2-Ethylamino-1-(3-hydroxyphenyl)ethanol Hydrochloride; Etilefrine hydrochloride (TN); dl-Effortil hydrochloride; Ethylephrine hydrochloride; dl-Etilefrin hydrochloride; dl-N-Ethylnorphenylephrine h

Indication

Disease Entry	ICD 11	Status	REF
Cardiovascular disease	BA00-BE2Z	Withdrawn from market	[1]
------------------------------------------------------------------------------------

ATC Code

C01CA01: Etilefrine

C01CA: Adrenergic and dopaminergic agents

C01C: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES

C01: CARDIAC THERAPY

C: CARDIOVASCULAR SYSTEM

C01CA01: Etilefrine

C01CA: Adrenergic and dopaminergic agents

C01C: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES

C01: CARDIAC THERAPY

C: CARDIOVASCULAR SYSTEM

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

181.23

Logarithm of the Partition Coefficient (xlogp)

0.1

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Bioavailability: 55% of drug becomes completely available to its intended biological destination(s) [2]
Clearance: The drug present in the plasma can be removed from the body at the rate of 14 mL/min/kg [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 2.2 hours [3]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 3.93971 micromolar/kg/day [4]
Unbound Fraction: The unbound fraction of drug in plasma is 0.77% [3]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 2.1 L/kg [3]

Chemical Identifiers

Formula: C10H15NO2
IUPAC Name: 3-[2-(ethylamino)-1-hydroxyethyl]phenol
Canonical SMILES: CCNCC(C1=CC(=CC=C1)O)O
InChI: InChI=1S/C10H15NO2/c1-2-11-7-10(13)8-4-3-5-9(12)6-8/h3-6,10-13H,2,7H2,1H3
InChIKey: SQVIAVUSQAWMKL-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3306
ChEBI ID: CHEBI:91518
CAS Number: 709-55-7
UNII: ZB6F8MY53V
DrugBank ID: DB08985
TTD ID: D01MXV
VARIDT ID: DR00028

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor (ADR)	TTVIREA	NOUNIPROTAC	Modulator	[1]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic cation transporter 3 (SLC22A3)	DT6201N	S22A3_HUMAN	Substrate	[5]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Solute carrier family 22 member 3 (SLC22A3)	OTQYGVXX	S22A3_HUMAN	Regulation of Drug Effects	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5	Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol. 2005 Dec 5;70(12):1851-60.